A tissue-engineered, osteoinductive bone graft substitute—ten years in development by scientists in Sweden and Switzerland—is poised to provide surgeons with a treatment option which combines the safety of autograft with the efficacy and reproducibility of synthetic osteoinductive products, thereby maximizing patient benefits. The Bio-ECM project, which seeks to develop and prove efficacy of an engineered decellularized human extracellular matrix (ECM), is supported by AO development incubator resources made available through the AO Innovation Translation Center (AO ITC) Technology Transfer.
Led by Prof Paul Bourgine of Lund University, Sweden, and Prof Ivan Martin, Department of Biomedicine, University of Basel, Switzerland, and executed by their respective teams, the Bio-ECM project represents a safe, osteoinductive alternative or adjunct to autografts which are the current gold standard for bone grafting. [Continue to read]
Designed to ...
Improve and accelerate bone growth in patients affected by bone defects
Provide a safe and efficient osteoinductive bone graft
Make an osteoinductive bone graft that is readily available off the shelf